Fenofibrate, pravastatin
Sold as Pravafen, Apotrigon
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pravafen 40/ 160 MG EACH HARD CAPSULE CONTAINS: PRAVASTATIN SODIUM EQUIVALENT TO:PRAVASTATIN 38,03 mg, FENOFIBRATE 160,0mg | 40/ 160 mg | 52076952/7.5/0769 | Registered | Not determined | None |
| Apotrigon 40/160 MG EACH CAPSULE CONTAINS :PRAVASTATIN SODIUM 38,03 mg FENOFIBRATE 160,0 mg | 40/160 mgCapsules | 55046855/7.5/0468Approved 27 April 2026 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Pravastatin
Consolidated Schedules 06 July 2026, line 7630
S3: Fenofibrate
Consolidated Schedules 06 July 2026, line 3567
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.